BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:
A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. The webcast will be archived on OraSure’s website and will be available for approximately 90 days.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
| Investor Contact: Jason Plagman VP, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: Amy Koch Director, Corporate Communications This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$2.99 |
| Daily Change: | 0.07 2.40 |
| Daily Volume: | 703,278 |
| Market Cap: | US$223.020M |
February 25, 2025 December 19, 2024 November 06, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
